A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. Pharmacyclics LLC, an AbbVie Company